TNFRSF8 and classic Hodgkin lymphoma: Bendamustine/fludarabine LDC conferred the lowest rate of CRS and best response, and was selected for an ongoing multicenter phase 2 CHARIOT study evaluating CD30-CAR T in R/R cHL who failed at least 3 prior lines of therapy including chemotherapy, brentuximab-vedotin and PD-1 inhibitor (NCT02259556) (150).